Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne to Acquire Single-Cell Sorting Firm Namocell

NEW YORK – Bio-Techne said on Wednesday that it has agreed to acquire single-cell sorting and dispensing firm Namocell.

Financial and other terms of the deal were not disclosed. The acquisition is expected to close in the first quarter of Bio-Techne’s fiscal year 2023. 

Namocell, founded in 2014 and based in Mountain View, California, currently offers multiple instruments, including Pala, a two-laser system with up to 11 fluorescent detection channels, and Hana, a single-laser system with two fluorescent detection channels. The platforms both use Namocell's proprietary technology, which combines microfluidics, flow cytometry, and liquid dispensing, to deliver single cells from samples to plates. So far, the firm has installed nearly 200 instruments, Bio-Techne said. 

The acquisition will complement Bio-Techne's cell and gene therapy business, and the firm anticipates "significant commercial synergies as we leverage our existing analytical tools sales force to penetrate this market opportunity," Bio-Techne President and CEO Chuck Kummeth said in a statement.

"Emerging technologies in cell-based research as well as next-generation therapeutics have created a need for fast, reliable, easy-to-use, and gentle cell sorting," he added. "Namocell's instruments offer unparalleled performance advantages over traditional flow cytometry and manual techniques and we anticipate continued traction with its leading portfolio of cell sorting technologies."

Namocell CEO Junyu Lin said in a statement that "Bio-Techne's global reach and strategic deployment in cell and gene therapy will enable Namocell to accelerate its penetration into the global markets, particularly in cell engineering and cell therapy applications, our biggest and fastest growing sectors."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.